New drug candidate reduces blood cholesterol

17:15, March 12, 2010      

Email | Print | Subscribe | Comments | Forum 

A thyroid-hormone-like substance that works specifically on the liver reduces blood cholesterol with no serious side effects, according to a clinical trial conducted by researchers from Karolinska Institutet, amongst other centres, published on Tuesday in the top-ranking scientific periodical the New England Journal of Medicine.

High cholesterol levels in the blood are primarily treated with a group of drugs called statins, but they are not always sufficiently effective and higher doses commonly cause adverse reactions, said researchers in a statement issued by the Karolinska Institute.

A team of researchers, including scientists from Karolinska Institute, have now shown in a clinical trial that a new drug substance called eprotirome can reduce blood cholesterol effectively in patients who have already received statins.

Patients who were given supplementary medication with eprotirome demonstrated levels of harmful blood fats that were up to 30 per lower than those of patients who received a placebo supplementary treatment.

The trial lasted three months and included a total of 189 patients. It remains to be studied whether the drug candidate will be equally safe and effective for a larger group of patients over a longer period of time, the statement said.

“This drug could help patients who react adversely to statins or be used as a supplementary treatment for those who don’t respond well to them,” said Professor Bo Angelin, who led the study.

Eprotirome mimics the natural ability of thyroid hormone to stimulate the metabolism of cholesterol, and exerts its effects exclusively on the liver. The development of similar non-selective drugs has previously been stopped on account of the serious adverse effects they have had on other organ systems (e.g. cardiac dilatation and osteoporosis) or on the physiological regulation of thyroid hormones, the statement said.

Eprotirome has been developed by pharmaceutical company KaroBio in Huddinge, which is financing and participating in the research, the statement added.

By Xuefei Chen, People's Daily Online reporter in Stockholm, ([email protected])
  • Do you have anything to say?

双语词典
dictionary

  
Special Coverage
Major headlines
Editor's Pick
  • Elie Saab Fall/Winter 2010/11 women's ready-to-wear fashion show
  • Snapshots from Int'l Tourism Bourse in Berlin
  • High school students in Taiwan attend coming-of-age rite
  • Envy? Baby otter dossing down on mom's stomach
  • 1000th day of Israeli blockade on Gaza Strip marked
  • 20th anniversary of Lithuania's declaration of independence
Most Popular
Hot Forum Dicussion